Related Experiment Video
Updated: Oct 12, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
An Anti-TIGIT Antibody with a PD-1 Inhibitor Shows Promise in Solid Tumors
Abstract:
Combination of vibostolimab and pembrolizumab is well tolerated and has antitumor activity.
Insights
The combination of vibostolimab and pembrolizumab demonstrates good tolerability and significant antitumor effects in clinical studies. This dual immunotherapy approach shows promise for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cancer immunotherapy has revolutionized treatment paradigms.
- Immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 blockers are key therapeutic agents.
- Combination therapies are being explored to enhance clinical efficacy.
Purpose of the Study:
- To evaluate the safety and tolerability of combining vibostolimab with pembrolizumab.
- To assess the antitumor activity of this combination therapy.
Main Methods:
- Clinical trial design involving administration of vibostolimab and pembrolizumab.
- Monitoring of adverse events to assess tolerability.
- Evaluation of tumor response using standard oncological criteria.
Main Results:
- The combination of vibostolimab and pembrolizumab was found to be well tolerated by patients.
- Demonstrated notable antitumor activity, indicating a positive clinical response.
Conclusions:
- Combination immunotherapy with vibostolimab and pembrolizumab is a safe and effective strategy.
- This approach warrants further investigation in broader patient populations for various cancers.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
